Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7102MR)

This product GTTS-WQ7102MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7102MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6581MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ3596MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ11421MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ10826MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ11005MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ7895MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ14415MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ9318MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW